Alps Advisors Inc. grew its position in shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) by 4.5% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 334,810 shares of the biopharmaceutical company’s stock after purchasing an additional 14,460 shares during the period. Alps Advisors Inc.’s holdings in Achillion Pharmaceuticals were worth $991,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Virtu Financial LLC purchased a new stake in shares of Achillion Pharmaceuticals during the first quarter valued at approximately $33,000. Acadian Asset Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the fourth quarter valued at approximately $41,000. Meeder Asset Management Inc. raised its stake in shares of Achillion Pharmaceuticals by 107.3% during the fourth quarter. Meeder Asset Management Inc. now owns 26,476 shares of the biopharmaceutical company’s stock valued at $42,000 after purchasing an additional 13,706 shares during the period. BNP Paribas Arbitrage SA raised its stake in shares of Achillion Pharmaceuticals by 934.3% during the first quarter. BNP Paribas Arbitrage SA now owns 31,444 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 28,404 shares during the period. Finally, Norges Bank purchased a new stake in shares of Achillion Pharmaceuticals during the fourth quarter valued at approximately $55,000. Institutional investors own 74.10% of the company’s stock.
Shares of NASDAQ:ACHN opened at $2.84 on Friday. The firm has a market capitalization of $377.31 million, a P/E ratio of -5.57 and a beta of 2.41. Achillion Pharmaceuticals, Inc. has a 12-month low of $1.29 and a 12-month high of $3.98.
A number of analysts recently issued reports on the stock. BidaskClub upgraded shares of Achillion Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 14th. Barclays lowered shares of Achillion Pharmaceuticals from an “equal weight” rating to an “underweight” rating and dropped their price target for the stock from $5.00 to $2.50 in a research note on Friday, May 3rd. William Blair restated an “outperform” rating on shares of Achillion Pharmaceuticals in a research note on Thursday, March 7th. Finally, Zacks Investment Research upgraded shares of Achillion Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, February 14th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $2.50.
COPYRIGHT VIOLATION WARNING: “Alps Advisors Inc. Has $991,000 Stake in Achillion Pharmaceuticals, Inc. (ACHN)” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this piece on another domain, it was illegally copied and republished in violation of international trademark and copyright legislation. The legal version of this piece can be viewed at https://www.baseballdailydigest.com/news/2019/05/10/alps-advisors-inc-has-991000-stake-in-achillion-pharmaceuticals-inc-achn.html.
Achillion Pharmaceuticals Profile
Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.
Further Reading: Terms to Better Understand Call Options
Want to see what other hedge funds are holding ACHN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN).
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.